Henrik Toft-Hansen

Dr. Henrik Toft-Hansen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LMLaura Massarenti
Laura Massarenti
CAChristina Aniol-Nielsen
Christina Aniol-Nielsen
CEChristian Enevold
Christian Enevold
HTHenrik Toft-Hansen
Henrik Toft-Hansen
CNClaus Henrik Nielsen
Claus Henrik Nielsen
Single nucleotide polymorphisms (SNPs) in insulin and insulin receptor genes may influence the interaction between the two molecules, as may anti-insulin antibodies (IAs), commonly found in patients with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D) treated with exogenous insulin. We examined the impact of two SNPs in the human insulin gene (INS), rs3842752 and rs689, and two in the insulin receptor gene (INSR) rs2245649 and rs2229429, on disease susceptibility, glycaemic control, and IAs formation in 100 T1D patients and 101 T2D patients treated with insulin. 79 individuals without diabetes were typed as healthy controls. The minor alleles of rs3842752 and rs689 in INS protected against T1D (OR: 0.50, p = 0.01 and OR: 0.44; p = 0.002, respectively). The minor alleles of both rs2245649 and rs2229429 in INSR were risk factors for poor glycaemic control (HbA1c ≥ 80 mmol/mol) in T1D (OR: 5.35, p = 0.009 and OR: 3.10, p = 0.01, respectively). Surprisingly, the minor alleles of rs2245649 and rs2229429 in INSR associated strongly with the absence of IAs in T1D (OR = 0.28, p = 0.008 and OR = 0.30, p = 0.002, respectively). In conclusion, the minor alleles of the investigated INS SNPs protect against T1D, and the minor alleles of the investigated INSR SNPs are associated with poor glycaemic control and the absence of IAs in T1D.

Verified
Journal Article
Open access
PDF file
HTHenrik Toft-Hansen
Henrik Toft-Hansen
CAChristina Aniol-Nielsen
Christina Aniol-Nielsen
DEDaniel Elias
Daniel Elias
MDMadeleine Dahlbäck
Madeleine Dahlbäck
PRPeter Rossing
Peter Rossing
HSHelene Solberg
Helene Solberg
The administration of insulin as a treatment for diabetes frequently leads to the formation of anti-insulin antibodies (IAs). The influence of these antibodies on the efficacy and safety of insulin therapy remains incompletely understood. This study presents a systematic, exploratory, cross-sectional analysis of the quantitative and qualitative properties of IAs in 101 patients with type 1 diabetes (T1D) and 101 patients with type 2 diabetes (T2D). The goal was to identify subpopulations of IAs that might impact glycemic control. We assessed the presence, titer, isotype, subclass, avidity, and in vitro neutralizing capacities of IAs, using glycated hemoglobin A1c (HbA1c) levels as an indicator of the clinical effectiveness of insulin. Our findings showed that 72% of individuals with T1D and 32% with T2D developed IAs, with IgG being the predominant isotype in both groups. Despite the presence of IAs, no in vitro neutralizing effect against insulin was observed, and there was no significant correlation between IA titer or avidity and HbA1c levels in either group. The results from this study demonstrate that while IAs are prevalent in both T1D and T2D, they do not have a significant clinical impact on the outcomes of insulin therapy in our study populations.

1 October 2021 in Journal of Immunological Methods
Verified
Journal Article
Closed access
CAChristina Aniol-Nielsen
Christina Aniol-Nielsen
HTHenrik Toft-Hansen
Henrik Toft-Hansen
MDMadeleine Dahlbäck
Madeleine Dahlbäck
CNClaus Henrik Nielsen
Claus Henrik Nielsen
HSHelene Solberg
Helene Solberg